CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.4700
-0.0300 (-0.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.5000
Open3.4800
Bid3.2000 x 900
Ask0.0000 x 1000
Day's Range3.3866 - 3.5200
52 Week Range2.0000 - 4.3100
Volume52,491
Avg. Volume179,603
Market Cap207.861M
Beta (3Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.4100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • What Makes Compugen (CGEN) a New Strong Buy Stock
    Zacks8 days ago

    What Makes Compugen (CGEN) a New Strong Buy Stock

    Compugen (CGEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • PR Newswire23 days ago

    Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting

    HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA. In a poster titled "Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors", the Company reported that the fifth dose level patient cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were reported. The poster presented at the meeting is available on Compugen's website.

  • PR Newswirelast month

    Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules

    NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801).  The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA", formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China. "We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market," stated Oramed CEO Nadav Kidron.

  • PR Newswirelast month

    Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management

    "My fellow board members and I are excited about Compugen's unique value proposition, its proven computational discovery platform, and differentiated therapeutic pipeline that is designed to address significant unmet needs in immuno-oncology," said Paul Sekhri, Chairman of the Board. "We have the highest confidence in this management team and employees whose talent and dedication made possible the acomplishments of 2018, including the intiation of two clinical trials as well as partnerships with Bristol-Myers Squibb and AstraZeneca.

  • PR Newswirelast month

    Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate

    HOLON, Israel, March 12, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter patents for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. The composition of matter patents expand Compugen's intellectual property protection for COM701 beyond the therapeutic use patent received as part of the Moonshot program in 2017 and cover exclusivity on COM701 in the United States for any purpose.

  • Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
    Zacks2 months ago

    Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4

    Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.

  • Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
    Zacks2 months ago

    Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?

    Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

  • PR Newswire2 months ago

    Compugen to Present at the Cowen and Company 39th Annual Health Care Conference

    HOLON, Israel , March 5, 2019 /PRNewswire/ --  Compugen Ltd.  (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced ...

  • PR Newswire2 months ago

    Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium

    HOLON, Israel, March 1, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress at The ASCO-SITC Clinical Immuno-Oncology Symposium.  In poster titled "A Phase 1 Study Evaluating COM701 in Patients With Advanced Solid Tumors," the Company reported that the third single subject dose cohort has been completed with no dose-limiting toxicities (DLTs) reported. "We continue to see significant interest in the study from investigators as they recognize the potential and differentiation of COM701 relative to other checkpoint inhibitors in development," said Henry Adewoye, M.D., Chief Medical Officer at Compugen.

  • PR Newswire2 months ago

    Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations

    Anticipated cost reductions expected to extend cash runway to allow the planned expansion of the ongoing COM701 Phase 1 study Company remains committed to investing in proprietary computational discovery ...

  • PR Newswire2 months ago

    Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET

    HOLON, Israel , Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...

  • PR Newswire3 months ago

    Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

    HOLON, Israel, Jan. 22, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpoint and the potential of COM701, Compugen's first-in-class inhibitory antibody targeting PVRIG, to serve as an effective cancer immunotherapy. The findings were published in two peer-reviewed papers in Cancer Immunology Research, an American Association for Cancer Research publication. Both papers were co-authored by Compugen's scientists in collaboration with scientists from Johns Hopkins University School of Medicine, headed by Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University, School of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, and Chairman of Compugen's Scientific Advisory Board.

  • How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own?
    Simply Wall St.3 months ago

    How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own?

    Every investor in Compugen Ltd. (NASDAQ:CGEN) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...

  • PR Newswire3 months ago

    Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium

    HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA. Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy.

  • GlobeNewswire5 months ago

    New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire5 months ago

    Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

    HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

  • Compugen (CGEN) Reports Q3 Loss
    Zacks6 months ago

    Compugen (CGEN) Reports Q3 Loss

    Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Compugen: 3Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...

  • PR Newswire6 months ago

    Compugen Reports Third Quarter 2018 Results

    HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?
    Zacks6 months ago

    Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?

    Compugen has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire6 months ago

    Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET

    HOLON, Israel , Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Benzinga6 months ago

    Don't Fixate On Market Woes, Just Make Your Trades

    Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.

  • Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
    Zacks6 months ago

    Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

    AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

  • Bristol-Myers Inks Deal and Invests $12 Million in Compugen
    Zacks6 months ago

    Bristol-Myers Inks Deal and Invests $12 Million in Compugen

    Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.